Reata Pharmaceuticals Inc (RETA) is a biopharmaceutical company that focuses on developing treatments for rare diseases with unmet medical needs. The company's lead product candidate is bardoxolone methyl, a small molecule designed to treat chronic kidney disease, pulmonary arterial hypertension, and other chronic diseases.
Reata Pharmaceuticals' pipeline also includes omaveloxolone, a product candidate for the treatment of Friedreich's ataxia, and RTA 901, a product candidate for the treatment of neurodegenerative diseases. The company is also developing other molecules to address additional therapeutic areas, including oncology and ophthalmology.
Founded in 2002 and based in Irving, Texas, Reata Pharmaceuticals is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol RETA.
Reata Pharmaceuticals Inc (RETA) is a biopharmaceutical company that focuses on developing treatments for rare diseases with unmet medical needs. The company's lead product candidate is bardoxolone methyl, a small molecule designed to treat chronic kidney disease, pulmonary arterial hypertension, and other chronic diseases.